||AFFILIATION||RELEVANT AREAS OF EXPERTISE
|William Janzen||Executive Director, Lead Discovery, Epizyme
||Lead Discovery, HTS, epigenetics
||Head of the Division of Rheumatology, University of Washington, Seattle||Autoimmunity, SLE, cGAS/STING
|David Siderovski||Chair of West Virginia University Dept. of Physiology, Pharmacology & Neuroscience||GPCRs/G proteins, pharmacology
Bill Janzen has been deeply involved in small molecule drug discovery with diverse targets using HTS for more than 25 years, including leadership positions at Eli Lilly, Amphora Discovery, Chaperone Therapeutics, and most recently at Epizyme, where he serves as Executive Director of Lead Discovery.
Keith Elkon is one of the world’s leading experts on the molecular and genetic basis for autoimmune diseases such as lupus and arthritis. His work has encompassed a large swath of autoimmune biology, reflected in over 200 publications. In addition to his academic roles, Dr. Elkon is a co-founder of Resolve Therapeutics, which currently has a biotherapeutic lead molecule, a human RNase-Fc fusion protein, in Phase II clinical trials for SLE.
David Siderovski is a thought leader in GPCR regulation and pharmacology. He discovered RGS proteins, the main type of GAP protein that modulates cellular signaling by GPCRs, and subsequently elucidated their key structural-functional properties using both X-ray crystallography and cell biology approaches.